About Antios Therapeutics
Antios Therapeutics is a Healthcare company based in Atlanta (United States) founded in 2018 by Abel De La Rosa and Idean Marvasty. Innovative therapies for treating and curing viral diseases are developed. It operates on a HealthTech model. Antios Therapeutics has raised $200.4 million across 4 funding rounds from investors including EPIQ, RA Capital and GordonMD Global Investments. Its chief executive, as recorded, is Abel De La Rosa. Antios Therapeutics offers products and services including ATI-2173 and 4th Generation CAM Program. Its focus areas include Biotechnology and Antiviral Drug Development. Its legal entity is Antios Therapeutics, Inc. Its competitors include SSI Strategy and Health Decisions.
Company details
Antios Therapeutics is engaged in the development of innovative therapies aimed at treating and potentially curing hepatitis B virus (HBV) and other viral diseases. The company is known for developing ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), which is combined with nucleoside analogues to inhibit HBV replication. Additionally, a 4th generation capsid assembly modulator (CAM) program is being advanced to support immune system clearance of HBV. Their work spans clinical trials and research presentations, contributing to advancements in antiviral treatments within the healthcare sector.
- Headquarters Atlanta, United States
- Founders Abel De La Rosa, Idean Marvasty
- SectorsHealthcare
- Email••••••••
- Website antiostherapeutics.com
- Social LinkedIn X
- Legal Name Antios Therapeutics, Inc.
- Total Equity Funding$200.4M (USD)
in 4 rounds
- Latest Funding Round$75M (USD), Series B
Nov 2021
- InvestorsEPIQ
& 21 more
Products & Services of Antios Therapeutics
Antios Therapeutics offers a comprehensive portfolio of products and services, including ATI-2173 and 4th Generation CAM Program.
ATI-2173 is developed as HBV polymerase inhibitor nucleotide.
CAM program is designed for targeted HBV virus clearance.
Funding Insights of Antios Therapeutics
Antios Therapeutics has successfully raised a total of $200.4M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $200.4M
- Total Rounds 4
- Last Round Series B — $75M
- First Round $25M
(Nov 2018)
- Investors Count 22
All 4 funding rounds of Antios Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $75M | Series B | – | GordonMD Global Investments, EPIQ | |
| Apr 2021 | $96M | Series B | – | Soleus Capital | |
| Aug 2020 | $4.4M | Series A | – | – | – |
| Nov 2018 | $25M | Series A | – | Lumira Ventures, Domain Associates |
22 investors in total: 22 institutional.
Investors in Antios Therapeutics
Antios Therapeutics has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include EPIQ, RA Capital and GordonMD Global Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment management services are provided in the biopharmaceutical sector. | 2021 | gordonmdglobalinvestment.com | Beverly Hills, United States | |
Diversified asset management services are offered by EPIQ. | 2018 | epiqcg.com | San Francisco, United States | |
Private equity investments are directed toward the healthcare sector. | avego.com | Alpharetta, United States | ||
Delos Capital is engaged in private equity and financial advisory services. | deloscap.com | New York City, United States | ||
Lumira Ventures is engaged in life sciences venture capital investment. | lumiraventures.com | Toronto, Canada | ||
| soleuscapital.com | ||||
Venture capital fund focused on tech startups | sixtydegreecapital.com | North York, Canada | ||
Healthcare startups are funded by this corporate-backed venture capital entity. | lifesciventure.com | New York, United States | ||
Seed & early stage sector-agnostic venture capital firm funding companies in the US | graventurefund.org | Atlanta, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States |
Investor details for Antios Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Antios Therapeutics
7 people are tracked at Antios Therapeutics (3 in leadership, 4 in board & advisors).
| Name | Role | Group |
|---|---|---|
Abel De La Rosa | Co-Founder & CEO | Leadership |
Idean Marvasty | Co-Founder | Leadership |
Mark Lockwood | Director, Process Research & Manufacturing | Leadership |
Benjamin Rovinski | Director | Board & advisors |
Scott Morenstein | Director | Board & advisors |
Iyona Rajkomar | Director | Board & advisors |
Craig Gordon | Director | Board & advisors |
Complete people profiles for Antios Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Antios Therapeutics
3 dated milestones of Antios Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Antios Therapeutics is founded.
- Funding First funding round of $25.0M.
- Funding Latest funding round, Series B, of $75.0M.
Competitors of Antios Therapeutics
Antios Therapeutics has 2 listed competitors in our database. They include SSI Strategy and Health Decisions.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ssistrategy.com | 2010 | Parsippany Troy Hills, United States | Pharmacovigilance and medical affairs services are offered for drug development. | |||
| healthdec.com | 1989 | Durham, United States | 110 | CRO focused on clinical trial services for data management, monitoring and biostatistics |
Detailed competitors of Antios Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Antios Therapeutics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Antios Therapeutics
Complete news archive for Antios Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antios Therapeutics
Antios Therapeutics was founded in 2018.
Antios Therapeutics is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Abel De La Rosa is the CEO of Antios Therapeutics, as recorded in our data. They have also founded this company.
Antios Therapeutics is a funded company, having raised a total of $200.4M across 4 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Nov 2018.
Antios Therapeutics is engaged in the development of innovative therapies aimed at treating and potentially curing hepatitis B virus (HBV) and other viral diseases. The company is known for developing ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), which is combined with nucleoside analogues to inhibit HBV replication. Additionally, a 4th generation capsid assembly modulator (CAM) program is being advanced to support immune system clearance of HBV. Their work spans clinical trials and research presentations, contributing to advancements in antiviral treatments within the healthcare sector.
Antios Therapeutics's top competitors include SSI Strategy and Health Decisions.
Antios Therapeutics offers ATI-2173 and 4th Generation CAM Program.
Antios Therapeutics has 22 investors. Key investors include EPIQ, RA Capital, GordonMD Global Investments, CAM Capital, and Avego.
Antios Therapeutics operates through Antios Therapeutics, Inc..